04:52 PM EDT, 03/23/2026 (MT Newswires) -- Context Therapeutics ( CNTX ) reported a FY net loss of $0.38 per diluted share late Monday, narrowing from a loss of $0.46 a year earlier.

Analysts polled by FactSet expected a loss of $0.35.

The company ended the year with $94.4 million in cash and equivalents. It expects this will be sufficient to fund operations into mid-2027.